Results 101 to 110 of about 7,833 (210)

Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance

open access: yes, 2022
Despite significant efficacy, one of the major limitations of small-molecule Bruton’s tyrosine kinase (BTK) agents is the presence of clinically acquired resistance, which remains a major clinical challenge.
Ji-Bo Kang (12576586)   +10 more
core   +1 more source

Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis

open access: yesJCI Insight, 2020
Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by chronic abscess formation and development of multiple draining sinus tracts in the groin, axillae, and perineum.
Johann E. Gudjonsson   +32 more
doaj   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1632-1649, July 2026.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan   +10 more
wiley   +1 more source

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

open access: yesImmunoTargets and Therapy, 2021
Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School ...
Arneson LC, Carroll KJ, Ruderman EM
doaj  

Stage‐Dependent Transcriptional Reprogramming of B‐Cell Receptor Signaling and Antigen Presentation During Bovine Leukemia Virus–Driven Lymphomagenesis

open access: yesAnimal Genetics, Volume 57, Issue 3, June 2026.
ABSTRACT Bovine leukemia virus (BLV), an oncogenic deltaretrovirus, establishes lifelong infection in cattle and induces enzootic bovine leukosis in a subset of animals following prolonged latency. Despite extensive evidence of immune dysregulation, stage‐specific transcriptional reprogramming of B cells, the primary viral reservoir remains ...
Mohammad Mehdi Akbarin   +6 more
wiley   +1 more source

Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma

open access: yes, 2018
Aberrant activation of anaplastic lymphoma kinase (ALK) can cause sporadic and familial neuroblastoma. Using a proteomics approach, we identified Bruton’s tyrosine kinase (BTK) as a novel ALK interaction partner, and the physical interaction was ...
Chan, Wai Yee   +39 more
core   +1 more source

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors

open access: yesFrontiers in Immunology, 2021
C. I. Edvard Smith   +3 more
doaj   +1 more source

Profound Sinoatrial Arrest Associated with Ibrutinib

open access: yesCase Reports in Oncological Medicine, 2017
Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia.
Kanupriya Mathur   +3 more
doaj   +1 more source

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study

open access: yesCancer Medicine, Volume 15, Issue 6, June 2026.
In a real‐world matched cohort study of treatment‐naïve TP53 wild‐type CLL patients, venetoclax plus obinutuzumab demonstrated significantly longer time to next treatment and improved 4‐year overall survival compared to first‐line acalabrutinib. Despite higher rates of cytopenias and infections, the venetoclax‐based regimen showed superior efficacy ...
Po‐Wei Liao   +4 more
wiley   +1 more source

"Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia "

open access: yesIranian Journal of Allergy, Asthma and Immunology, 2004
X-linked agammaglobulinemia (XLA) is an immunodeficiency caused by mutations in the Bruton tyrosine kinase (Btk) gene. In order to identify the mutations in Btk gene in Iranian patients with antibody deficiency, 13 male patients with an XLA phenotype ...
"Asghar Aghamohammadi   +11 more
doaj  

Home - About - Disclaimer - Privacy